Please provide your email address to receive an email when new articles are posted on . ADVM-062, a novel gene therapy candidate, received orphan drug designation from the FDA for the treatment of ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results